Humanigen Inc (fka HGENQ)

[10nisman]

If we annualize Q3 G&A, we are looking at $26M in expense. If we double that in FY22, for CMC-required manufacturing capacity, that's $52M.

$52 million raised at $4 per share = 13 million new shares. That's a lot of dilution before paying for any production, trials, etc.

If Clinigen can manage to sell 10% of our inventory in the 16 European countries in which they operate, that's gross revenue of $100M. I'd say that revenue stream makes us more resilient, and less fragile, as a company.

What are you talking about? First off, there are no revenues (None, Zero, Zilch) and there won't be any material revenues until there's regulatory approval. Second, a belief the current inventory is worth anywhere close to $100 million would be completely absurd let alone $1 billion.

There are very good reasons HGEN is trading sub $4 and down 87+% from its 52 week high. And sadly, it has nothing to do with shorts.